Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (29590)	12/13/1999 3:22:00 PM
From: celeryroot.com	Read Replies (1) \| Respond to of 32384

not sure if that for early or late also , it is my understanding that near a 100% of patients become late stage

To: Mudcat who wrote (29590)	12/13/1999 3:54:00 PM
From: Scott	Read Replies (1) \| Respond to of 32384

What the panel recommended that the FDA ask for is a Phase IV study, which is not at all uncommon. All it means is that the FDA wants to see how this drug stacks up in a "face-to-face" comparison with a currently available drug. Once the FDA finds a drug "safe and effective", as the panel has recommended that they do, they are not going to pull it from the market on the basis of Ph. IV study results showing it is not quite as good as another treatment, just if it has bad sideeffects, etc. SUch a comparison study is almost never done in a Ph. II or III study, and is useful for the medical community and the FDA to have results on. Nothing at all for investors to be unhappy about. Particularly since there are so few alternative treatments available for this disease in late stages. I am curious what the panel recommended that Tangretin be compared against.